Mortality rates for patients with non-small-cell lung carcinoma (NSCLC) dropped sharply in 2020 following the approval of a number of drugs targeting the EGFR mutation, which is common in Asian patient populations. In this recent webinar, Dr Noemi Reguart, a medical oncologist at the Hospital Clinic in Barcelona, stresses the importance of using biomarker testing as a key diagnostic tool for identifying EGFR mutation positive patients.

Dr Reguart shares her experience as a medical oncologist and her thoughts on what recent clinical trial data means for clinicians. She emphasises that greater communication between clinicians and pathologists is critical for rapid turnaround time for diagnostic results and ultimately better disease management of NSCLC patients. She concludes by talking about where the field is headed and highlights exciting and promising ongoing clinical trials.